Consensus iTeos Therapeutics, Inc.

Equities

ITOS

US46565G1040

Market Closed - Nasdaq Other stock markets 01:30:00 03/05/2024 am IST			5-day change	1st Jan Change
11.49 ^USD	-2.59%		+8.40%	+4.93%

13/03	Top Premarket Decliners	MT
12/03	JPMorgan Adjusts Price Target on iTeos Therapeutics to $27 From $29, Maintains Overweight Rating	MT

Evolution of the average Target Price on iTeos Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

5bde9c8c5e.iSH9khWtEzBXt2Kodzh7BA9Ke9jsDzOfRluXyYwFbVw.5HvIpE3PS2kSwhPMFHlNZTcyFIK1a2v0MTmvgf9mORu5W7H8Yeg-Amf8Lw~725fd0716de9e4c6935af05189ec9eb4

Analyst Recommendations on iTeos Therapeutics, Inc.

JPMorgan Adjusts Price Target on iTeos Therapeutics to $27 From $29, Maintains Overweight Rating	12/03	MT
Wedbush Adjusts iTeos Therapeutics Price Target to $18 From $25, Maintains Outperform Rating	06/03	MT
JPMorgan Cuts Price Target on iTeos Therapeutics to $29 From $32, Maintains Overweight Rating	13/11	MT
HC Wainwright Adjusts Price Target on iTeos Therapeutics to $44 From $54, Maintains Buy Rating	09/23/09	MT
JPMorgan Chase Adjusts Price Target on iTeos Therapeutics to $32 From $34, Maintains Overweight Rating	16/23/16	MT
Wedbush Lowers iTeos Therapeutics' Price Target to $33 From $45 Following Model Update; Keeps Outperform Rating	16/23/16	MT
Wedbush Lifts Price Target on iTeos Therapeutics to $45 From $42, Keeps Outperform Rating	11/22/11	MT
Wedbush Adjusts Price Target on ITeos Therapeutics to $42 From $49, Citing EOS-448 Launch Estimates; Outperform Rating Kept	13/22/13	MT
Piper Sandler Adjusts Price Target on ITeos Therapeutics to $34 From $42, Reiterates Overweight Rating	12/22/12	MT
Wedbush Removes Outperform-Rated ITeos Therapeutics From Best Ideas List; Price Target is $49	06/22/06	MT
Wedbush Lifts ITeos Therapeutics' Price Target to $49 From $48; Outperform Rating Kept	16/21/16	MT
HC Wainwright Adjusts iTeos Therapeutics' Price Target to $54 from $37, Keeps Buy Rating	13/21/13	MT
Piper Sandler Adjusts iTeos Therapeutics' Price Target to $42 From $50, Reiterates Overweight Rating	11/21/11	MT
Wedbush Lowers ITeos Therapeutics' Price Target to $48 From $52; Outperform Rating Kept	11/21/11	MT
ITEOS THERAPEUTICS : Wedbush Lifts ITeos Therapeutics' Price Target to $52 From $50, Keeps Outperform Rating	13/21/13	MT
ITEOS THERAPEUTICS : Wedbush Adjusts ITeos Therapeutics' Price Target to $50 From $52, Keeps Outperform Rating	15/21/15	MT
ITEOS THERAPEUTICS : SVB Leerink Adjusts Price Target on ITeos Therapeutics to $45 From $60, Maintains Outperform Rating	19/21/19	MT
ITEOS THERAPEUTICS : HC Wainwright Starts ITeos Therapeutics at Buy With $37 Price Target	05/21/05	MT
ITEOS THERAPEUTICS : SVB Leerink Adjusts Price Target on iTeos Therapeutics to $60 From $37, Maintains Outperform Rating	06/21/06	MT
ITEOS THERAPEUTICS : Wedbush Raises Price Target for iTeos Therapeutics Ahead of Potentially Upbeat EOS-448 Data, Maintains Outperform Rating	25/21/25	MT
ITEOS THERAPEUTICS : Wedbush Adjusts Price Target on ITeos Therapeutics to $46 From $45, Keeps Outperform Rating	13/20/13	MT